PF 4518600

Drug Profile

PF 4518600

Alternative Names: PF-04518600; PF-8600

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; University of Southern California
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma; Solid tumours
  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 27 Dec 2017 Phase-Ib/II clinical trials in Acute myeloid leukaemia (Combination therapy) in USA (IV) (NCT03390296)
  • 27 Dec 2017 Phase-Ib/II clinical trials in Acute myeloid leukaemia (Monotherapy) in USA (IV) (NCT03390296)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top